The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since ...

Vertex Pharmaceuticals Stock Up 0.5 % Vertex Pharmaceuticals stock opened at $488.29 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Mike Lee, R-Utah, who said "Not another penny to Ukraine" in response to a post from another user questioning if U.S. taxpayers paid for a huge Ukrainian flag that was unfurled in front of the ...

On March 7, 2025, Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in ...

The Week is part of Future US Inc, an international media group and leading digital publisher. Visit our corporate site.

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

British soldiers read a map in the trenches of the Western Front during World War One. The trenches were dug out of the mud of the battlefields and lined with wood and barbed wire. Watch this ...